Becker Microbial Products, Inc., (BMP) began to invest in biotechnology in 1985. This investment was structured around the acquisition of proprietary BT technology through several venture capital agreements with research departments at Tel Aviv and Hebrew Universities in Israel.
BMP also financed the construction of a 20,000 liter fermentation pilot plant in Israel. This plant was instrumental in the development of fermentation and formulation technology that is state of the art and is as good as or better than that being employed by the leading manufacturers of BT in the United States.
All Becker products are produced from two strains of Bacillus thuringiensis. These are B. thuringiensis subspecies kurstaki strain BMP 123 and Bacillus thuringiensis subspecies israelensis strain BMP 144. All formulations based on these strains are registered with the United States Environmental Protection Agency.